Home › Triple-Negative Breast Cancer › Washington › Tacoma
Triple-Negative Breast Cancer clinical trials in Tacoma, WA
3 studies for Triple-Negative Breast Cancer are looking for participants at sites in and around Tacoma (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
RecruitingPhase 3
- Northwest Medical Specialties, PLLC ( Site 0093), Tacoma
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
RecruitingPhase 3
- Northwest Medical Specialties, PLLC ( Site 0067), Tacoma
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
RecruitingPhase 3
- MultiCare Regional Cancer Center - Tacoma, Puyallup · 8 mi away
- Northwest Medical Specialties, PLLC, Puyallup · 8 mi away
- Providence Regional Cancer System, Lacey · 23 mi away
Triple-Negative Breast Cancer trials in other cities
- Houston, TX42 studies
- New York City, NY31 studies
- Nashville, TN28 studies
- Los Angeles, CA27 studies
- Boston, MA26 studies
- San Antonio, TX23 studies
- St. Louis, MO21 studies
- Arlington, VA20 studies
- Atlanta, GA20 studies
- Dallas, TX18 studies
- Chicago, IL16 studies
- Columbus, OH16 studies
Other studies in Tacoma
- Non-Small Cell Lung Cancer20 studies
- Breast Cancer18 studies
- Ulcerative Colitis15 studies
- Multiple Myeloma13 studies
- Prostate Cancer11 studies
- Crohn's Disease11 studies
- Colorectal Cancer9 studies
- Metastatic Cancer9 studies
- Melanoma7 studies
- Ovarian Cancer7 studies
- Stomach Cancer6 studies
- Esophageal Cancer6 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.